Amyris (NASDAQ:AMRS)‘s stock had its “hold” rating reaffirmed by investment analysts at Cowen in a note issued to investors on Wednesday, November 29th. They presently have a $4.00 price target on the biotechnology company’s stock. Cowen’s price objective suggests a potential upside of 11.11% from the stock’s current price.
AMRS has been the subject of a number of other research reports. Zacks Investment Research downgraded shares of Amyris from a “buy” rating to a “hold” rating in a research report on Monday, October 23rd. HC Wainwright reaffirmed a “buy” rating and issued a $15.00 target price on shares of Amyris in a report on Wednesday, November 15th. Finally, ValuEngine upgraded shares of Amyris from a “strong sell” rating to a “sell” rating in a report on Friday, September 1st. One investment analyst has rated the stock with a sell rating, two have given a hold rating and two have given a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and an average target price of $20.69.
Shares of Amyris (NASDAQ:AMRS) opened at $3.60 on Wednesday. Amyris has a 52-week low of $1.86 and a 52-week high of $12.45. The company has a current ratio of 0.92, a quick ratio of 0.82 and a debt-to-equity ratio of -0.78.
Amyris (NASDAQ:AMRS) last announced its quarterly earnings results on Tuesday, November 14th. The biotechnology company reported ($0.81) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.77) by ($0.04). The company had revenue of $24.20 million during the quarter, compared to analysts’ expectations of $36.30 million. The firm’s quarterly revenue was down 8.8% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.07) EPS. sell-side analysts anticipate that Amyris will post -3.32 EPS for the current fiscal year.
Several large investors have recently made changes to their positions in AMRS. Tanaka Capital Management Inc. grew its position in shares of Amyris by 72.0% during the 3rd quarter. Tanaka Capital Management Inc. now owns 528,549 shares of the biotechnology company’s stock valued at $1,691,000 after buying an additional 221,295 shares during the last quarter. Carl Domino Inc acquired a new stake in Amyris during the third quarter valued at approximately $182,000. KBC Group NV lifted its stake in Amyris by 228.4% during the third quarter. KBC Group NV now owns 60,154 shares of the biotechnology company’s stock valued at $192,000 after purchasing an additional 41,834 shares during the last quarter. Finally, Bank of New York Mellon Corp raised its holdings in shares of Amyris by 16.3% during the second quarter. Bank of New York Mellon Corp now owns 32,768 shares of the biotechnology company’s stock valued at $104,000 after acquiring an additional 4,603 shares during the period. 22.84% of the stock is owned by institutional investors and hedge funds.
COPYRIGHT VIOLATION NOTICE: “Amyris (AMRS) Receives Hold Rating from Cowen” was originally posted by TrueBlueTribune and is owned by of TrueBlueTribune. If you are accessing this piece of content on another domain, it was illegally copied and reposted in violation of U.S. & international trademark and copyright law. The legal version of this piece of content can be accessed at https://www.truebluetribune.com/2017/12/12/amyris-amrs-hold-rating-reaffirmed-at-cowen.html.
Amyris, Inc is an integrated industrial biotechnology company. The Company is engaged in research and development and sales of fuels and farnesene-derived products. It is applying its industrial synthetic biology platform to engineer, manufacture and sell products into a range of consumer and industrial markets, including cosmetics, flavors and fragrances (F&F), solvents and cleaners, polymers, lubricants, healthcare products and fuels.
Receive News & Ratings for Amyris Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amyris Inc. and related companies with MarketBeat.com's FREE daily email newsletter.